Garcia Borrega, J, Gödel, P, Rüger, MA, Onur, OA, Shimabukuro-Vornhagen, A, Kochanek, M, Böll, B. In the eye of the storm: Immune-mediated toxicities associated with CAR-T cell therapy. HemaSphere. 2019;3(2):e191. 29. Doi: 10.1097/HS9.0000000000000191.CrossRefGoogle ScholarPubMed

Neelapu, SS. Managing the toxicities of CAR T-cell therapy. Hematological Oncology. 2019;37(S1): 48–52. Doi: 10.1002/hon.2595.CrossRefGoogle ScholarPubMed

Riegler, LL, Jones, GP, Lee, DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Therapeutics and Clinical Risk Management. 2019;15:323‒335. Doi: 10.2147/TCRM.S150524.CrossRefGoogle ScholarPubMed

Sheth, VS, Gauthier, J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021; 56:552–566. Doi: 10.1038/s41409-020-01134-4.CrossRefGoogle ScholarPubMed

Albarrán, V, Chamorro, J, Rosero, DI, Saavedra, C, Soria, A, Carrato, A, Gajate, P. Neurologic toxicity of immune checkpoint inhibitors: A review of literature. Frontiers in Pharmacology. 2022; 13. Doi: 10.3389/fphar.2022.774170.CrossRefGoogle ScholarPubMed

Cappelli, LC, Gutierrez, AK, Bingham, CO III, Shah, AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care and Research. 2017;69(11):1751–1763. Doi: 10.1002/acr.23177.CrossRefGoogle ScholarPubMed

Castillo, RM, Sandefur, BJ, Finch, AS, Richter, MD, Thanarajasingam, U. Clinical presentations and outcomes of patients receiving immune checkpoint inhibitors presenting to the emergency department. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2021;5(6):1029–1035. Doi:10.1016/j.mayocpiqo.2021.09.007.Google ScholarPubMed

Del Rivero, J, Cordes, LM, Klubo‐Gwiezdzinska, J, Madan, RA, Nieman, LK, Gulley, JL. Endocrine-related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management. The Oncologist. 2020;25(4):290–300. Doi: 10.1634/theoncologist.2018-0470.CrossRefGoogle ScholarPubMed

Hryniewicki, AT, Wang, C, Shatsky, RA, Coyne, CJ. Management of immune checkpoint inhibitor toxicities: A review and clinical guideline for emergency physicians. Journal of Emergency Medicine. 2018 Oct;55(4):489–502. Doi: 10.1016/j.jemermed.2018.07.005. Epub 2018 Aug 16. PMID: 30120013.CrossRefGoogle ScholarPubMed

Lauwyck, J, Beckwée, A, Santens, A, Schwarze, JK, Awada, G, Vandersleyen, V, Aspeslagh, S, Neyns, B. C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Research. 2021 Aug 1;31(4):371–377. Doi: 10.1097/CMR.0000000000000748. PMID: 34054056.CrossRefGoogle ScholarPubMed

Muntyanu, A, Netchiporouk, E, Gerstein, W, Gniadecki, R, Litvinov, IV. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: A dermatology perspective on management . Journal of Cutaneous Medicine and Surgery. 2021 Jan‒Feb;25(1):59–76. Doi: 10.1177/1203475420943260. Epub 2020 Aug 3. PMID: 32746624.CrossRefGoogle ScholarPubMed

Nso, N, Antwi-Amoabeng, D, Beutler, BD, et al. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World Journal of Cardiology. 2020;12(11):584–598. Doi: 10.4330/wjc.v12.i11.584.CrossRefGoogle ScholarPubMed

Rapoport, BL, Shannon, VR, Cooksley, T, Johnson, DB, Anderson, L, Blidner, AG, Tintinger, GR, Anderson, R. Pulmonary toxicities associated with the use of immune checkpoint inhibitors: An update from the immuno-oncology subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Frontiers in Pharmacology. 2021. Doi: 10.3389/fphar.2021.743582.CrossRefGoogle Scholar

Schneider, BJ, Naidoo, J, Santomasso, BD, Lacchetti, C, Adkins, S, Anadkat, M, Atkins, MB, Brassil, KJ, Caterino, JM, Chau, I, Davies, MJ, Ernstoff, MS, Fecher, L, Ghosh, M, Jaiyesimi, I, Mammen, JS, Naing, A, Nastoupil, LJ, Phillips, T, Porter, LD, Reichner, CA, Seigel, C, Song, JM, Spira, A, Suarez-Almazor, M, Swami, U, Thompson, JA, Vikas, P, Wang, Y, Weber, JS, Funchain, P, Bollin, K. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. Journal of Clinical Oncology. 2021 Dec 20;39(36):4073–4126. Doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. Erratum in: Journal of Clinical Oncology. 2022 Jan 20;40(3):315. PMID: 34724392.CrossRefGoogle ScholarPubMed

Shah, M, Rajha, E, DiNardo, C, Muckey, E, Wierda, WG, Yeung, SJ. Adverse events of novel therapies for hematologic malignancies: What emergency physicians should know. Annals of Emergency Medicine. 2020 Feb;75(2):264–286. Doi: 10.1016/j.annemergmed.2019.07.015. Epub 2019 Sep 24. PMID: 31561995.CrossRefGoogle ScholarPubMed

Trinh, S, Le, A, Gowani, S, La-Beck, NM. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: A minireview of current clinical guidelines. Asia-Pacific Journal of Oncology Nursing. 2019; 6(2):154–160. Doi: 10.4103/apjon.apjon_3_19.CrossRefGoogle ScholarPubMed

Yeung, SJ, Qdaisat, A, Chaftari, P, Lipe, D, Merlin, J, Rajha, E, Wechsler, A, Sandoval, M, Viets, J, Al-Breiki, A, Shah, M, Pandey, R, Kamal, M, Khattab, O, Toale, K, Wattana, M, Elsayem, A, Gaeta, S, Brock, P, Reyes-Gibby, C, Alagappan, K. Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. Journal of the American College of Emergency Physicians Open. 2020 Aug 30;1(6):1637–1659. Doi: 10.1002/emp2.12209. PMID: 33392573; PMCID: PMC7771833.CrossRefGoogle ScholarPubMed

Fathi, AT, Eytan, M. Stein, EM, DiNardo, CD, Levis, MJ, Montesinos, P, de Botton, S. Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. American Journal of Hematology. 2021; 96(6):735–746. Doi: 10.1002/ajh.26142.CrossRefGoogle ScholarPubMed

Sanz, MA, Montesinos, P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014; 123(18):2777–2782. Doi: 10.1182/blood-2013-10-512640.CrossRefGoogle ScholarPubMed

Stahl, M, Tallman, MS. Differentiation syndrome in acute promyelocytic leukaemia. British Journal of Haematology. 2019;187(2):157–162. Doi: 10.1111/bjh.16151.CrossRefGoogle ScholarPubMed

Alada ḡ, E, Kelkitli, E, Göker, H. Acute graft-versus-host disease: A brief review. Turkish Journal of Haematology. 2020;37(1):1–4. Doi: 10.4274/tjh.galenos.2019.2019.0157.Google Scholar

Flowers, ME, Inamoto, Y, Carpenter, PA, Lee, SJ, Kiem, H-P. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–3219. Doi: 10.1182/blood-2010-08-302109.CrossRefGoogle ScholarPubMed

Hamilton, BK. Updates in chronic graft-versus-host disease. Hematology. American Society of Hematology, Education Program. 2021;1:648–654. Doi: 10.1182/hematology.2021000301.CrossRefGoogle Scholar

Justiz Vaillant, AA, Modi, P, Mohammadi, O. Graft versus host disease. [Updated May 1, 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available at: www.ncbi.nlm.nih.gov/books/NBK538235/Google Scholar

Moreno, DF, Cid, J. Graft-versus-host disease. Enfermedad del injerto contra el receptor. Medicina Clínica. 2019;152(1):22–28. Doi: 10.1016/j.medcli.2018.07.012.CrossRefGoogle Scholar

Ramachandran, V, Kolli, SS, Strowd, LC. Review of graft-versus-host disease. Dermatologic Clinics. 2019;37(4):569–582. Doi: 10.1016/j.det.2019.05.014.CrossRefGoogle ScholarPubMed

Song, I Chin, AY, Han, J, Kim, DH, Lee, KS, Kim, TS, Chung, MJ. CT findings of late-onset noninfectious pulmonary complications in patients with pathologically proven graft-versus-host disease after allogeneic stem cell transplant. American Journal of Roentgenology. 2012;199(3):581–587. Doi: 10.2214/AJR.11.7165.CrossRefGoogle ScholarPubMed

Williams, JC, Jorgensen, SA, Towbin, AJ, Towbin, R. Graft versus host disease. Applied Radiology. 2017;46(12).Google Scholar

Wingard, JR, Piantadosi, S, Vogelsang, G, Farmer, E, Jabs, D, Levin, L, Beschorner, W, Cahill, R, Miller, D, Harrison, D. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74(4):1428–1435.CrossRefGoogle ScholarPubMed

Zeiser, R, and Blazar, BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. The New England Journal of Medicine. 2017;377(26):2565–2579. Doi: 10.1056/NEJMra1703472.CrossRefGoogle ScholarPubMed

Bewersdorf, JP, Zeidan, AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: Can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020;9(10):2310. Doi: 10.3390/cells9102310.CrossRefGoogle ScholarPubMed

Ghosh, K, Malik, K, Das, KC. Serum and leukocyte lactate dehydrogenase activity in leukaemias. Haematologia. 1988;21(4) :227–232.Google ScholarPubMed

Macaron, W, Sargsyan, Z, Short, NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leukemia & Lymphoma. 2022;63(8). Doi: 10.1080/10428194.2022.2056178.CrossRefGoogle ScholarPubMed

Stefanski, M, Jamis-Dow, C, Bayerl, M, Desai, RJ, Claxton, DF, Van de Louw, A. Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia: A retrospective cohort study of 73 patients. Medicine. 2016;95(44):e5285. Doi: 10.1097/MD.0000000000005285.CrossRefGoogle ScholarPubMed

Ahn, S, Rice, TW, Yeung, S-C, Cooksley, T. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: Analysis of data from three emergency departments of cancer centers in three continents. Supportive Care in Cancer. 2018;26(5):1465–1470.Google ScholarPubMed

Baugh, CW, Wang, TJ, Caterino, JM, Baker, ON, Brooks, GA, Reust, AC, Pallin, DJ. Emergency department management of patients with febrile neutropenia: Guideline concordant or overly aggressive? Academic Emergency Medicine. 2017;24(1):83–91.CrossRefGoogle ScholarPubMed

Casanovas-Blanco, M, Serrahima-Mackay, A. Febrile neutropenia management in cancer patients receiving anti-cancer agents’ treatment: Deepening the search to offer the best care. A critical review follow-up. Critical Reviews in Oncology/Hematology. 2020;153:103042.CrossRefGoogle Scholar

Costa, RT, Nassar, AP Jr, Caruso, P. Accuracy of SOFA, qSOFA, and SIRS scores for mortality in cancer patients admitted to an intensive care unit with suspected infection. Journal of Critical Care. 2018 Jun;45: 52–57.CrossRefGoogle Scholar

Gerritsen, MG, Willemink, MJ, Pompe, E, van der Bruggen, T, van Rhenen, A, Lammers, JW, Wessels, F, Sprengers, RW, de Jong, PA, Minnema, MC. Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography. PLoS ONE. 2017 Feb 24;12(2):e0172256.CrossRefGoogle ScholarPubMed

Lee, NH, Kang, J-M, Lee, JW, Huh, HJ, Lee, NY, Yoo, KH, Sung, KW, Koo, HH, Kim, Y-J. Cefepime versus cefepime plus amikacin as an initial antibiotic choice for pediatric cancer patients with febrile neutropenia in an era of increasing cefepime resistance. Pediatric Infectious Disease Journal. 2020; 39:931‒936.CrossRefGoogle Scholar

Long, B, Koyfman, A. Oncologic emergencies: The fever with too few neutrophils. Journal of Emergency Medicine. 2019;57(5):689‒700.CrossRefGoogle ScholarPubMed

Cairo, MS, Coiffier, B, Reiter, A, Younes, A, TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. British Journal of Haematology. 2010;149(4):578–586. Doi: 10.1111/j.1365-2141.2010.08143.CrossRefGoogle ScholarPubMed

Klemencic, S, Perkins, J. Diagnosis and management of oncologic emergencies. Western Journal of Emergency Medicine. 2019 Mar;20(2):316–322. Doi: 10.5811/westjem.2018.12.37335. Epub 2019 Feb 14.CrossRefGoogle ScholarPubMed

Lipe, D,, Wattana, M. Tumor lysis syndrome. In: CorePendium, available at: www.emrap.org/corependium/, e-Book 2019.Google Scholar